| Year |
Citation |
Score |
| 2019 |
Paudel N, Schulze D, Gentzler RD, Evens AM, Helenowski I, Dillehay G, Frankfurt O, Mehta J, Donnelly ED, Gordon LI, Winter JN, Mittal BB. Patterns of Failure and Survival Outcomes After Total Lymphoid Irradiation and High-Dose Chemotherapy With Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma. International Journal of Radiation Oncology, Biology, Physics. PMID 30763660 DOI: 10.1016/j.ijrobp.2019.02.007 |
0.36 |
|
| 2019 |
Al-Mansour Z, Li H, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Smith SM, Marcellus DC, Barton KP, Mills GM, LeBlanc M, et al. Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. Leukemia & Lymphoma. 1-8. PMID 30628511 DOI: 10.1080/10428194.2018.1563691 |
0.303 |
|
| 2016 |
Puvvada SD, Stiff PJ, Leblanc M, Cook JR, Couban S, Leonard JP, Kahl B, Marcellus D, Shea TC, Winter JN, Li H, Rimsza LM, Friedberg JW, Smith SM. Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. British Journal of Haematology. PMID 27072903 DOI: 10.1111/Bjh.14100 |
0.331 |
|
| 2016 |
Yap TA, Johnson PWM, Winter J, Leonard J, Giulino-Roth L, Horner T, Radswillas K, Carver J, Dhar A. A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin’s lymphomas (NHL), multiple myeloma (MM) and solid tumor. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps2595 |
0.337 |
|
| 2014 |
Nelson BP, Abdul-Nabi A, Goolsby C, Winter J, Peterson L. Characterization of tissue findings in bone marrow biopsy specimens with small monoclonal B-cell populations. American Journal of Clinical Pathology. 141: 687-96. PMID 24713740 DOI: 10.1309/Ajcpd5Tobdju4Gko |
0.356 |
|
| 2014 |
Gentzler RD, Evens AM, Rademaker AW, Weitner BB, Mittal BB, Dillehay GL, Petrich AM, Altman JK, Frankfurt O, Variakojis D, Singhal S, Mehta J, Williams S, Kaminer L, Gordon LI, ... Winter JN, et al. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. British Journal of Haematology. 165: 793-800. PMID 24628515 DOI: 10.1111/bjh.12824 |
0.344 |
|
| 2013 |
Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. The New England Journal of Medicine. 369: 1681-90. PMID 24171516 DOI: 10.1056/Nejmoa1301077 |
0.327 |
|
| 2012 |
Vidula N, Jovanovic B, Winter J, Mehta J, Singhal S, Williams S, Frankfurt O, Altman JK, Monreal J, Evens AM, Gordon LI. Early and Late Complications Associated with Busulfan, Cyclophosphamide, and Etoposide (Bu/Cy/VP-16) Conditioning Followed by Allogeneic or Autologous Stem Cell Transplantation in Relapsed/Refractory Non-Hodgkin'S Lymphoma Biology of Blood and Marrow Transplantation. 18. DOI: 10.1016/J.Bbmt.2011.12.239 |
0.434 |
|
| 2010 |
Williams ME, Dreyling M, Winter J, Muneer S, Leonard JP. Management of mantle cell lymphoma: key challenges and next steps. Clinical Lymphoma, Myeloma & Leukemia. 10: 336-46. PMID 21030346 DOI: 10.3816/Clml.2010.N.066 |
0.394 |
|
| 2010 |
Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, Gimelfarb A, Hattersley E, Mauro LA, Jovanovic B, Chadburn A, Stiff P, Winter JN, Mehta J, Van Besien K, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1038-46. PMID 20085936 DOI: 10.1200/Jco.2009.25.4961 |
0.315 |
|
| 2010 |
Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD, Bolwell BJ, Freytes CO, Gale RP, Goldstein SC, Hale GA, Inwards DJ, Klumpp TR, Marks DI, Maziarz RT, ... ... Winter JN, et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 16: 35-45. PMID 20053330 DOI: 10.1016/j.bbmt.2009.08.011 |
0.355 |
|
| 2009 |
Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen YB, Freytes CO, Gale RP, Hale GA, Ilhan O, Khoury HJ, Lister J, ... ... Winter JN, et al. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 15: 1455-64. PMID 19822306 DOI: 10.1016/j.bbmt.2009.07.017 |
0.359 |
|
| 2009 |
Gopal AK, Winter JN. Radioimmunoconjugates in hematopoietic stem cell transplantation. Cancer Treatment and Research. 144: 299-315. PMID 19779884 DOI: 10.1007/978-0-387-78580-6_13 |
0.31 |
|
| 2009 |
Mehta J, Mehta J, Frankfurt O, Altman J, Evens A, Tallman M, Gordon L, Williams S, Winter J, Krishnamurthy J, Duffey S, Singh V, Meagher R, Grinblatt D, Kaminer L, et al. Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. Leukemia & Lymphoma. 50: 1434-41. PMID 19603344 DOI: 10.1080/10428190903085944 |
0.481 |
|
| 2008 |
Evens AM, Winter JN, Hou N, Nelson BP, Rademaker A, Patton D, Singhal S, Frankfurt O, Tallman MS, Rosen ST, Mehta J, Gordon LI. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. British Journal of Haematology. 140: 385-93. PMID 18162124 DOI: 10.1111/j.1365-2141.2007.06908.x |
0.371 |
|
| 2008 |
Krishnamurthy J, Singh V, Frankfurt O, Evens AM, Altman J, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Actual (ABW) or Ideal (IBW) Body Weight to Calculate CD34+ Cell Dose in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Myeloma? Blood. 112: 4455-4455. DOI: 10.1182/Blood.V112.11.4455.4455 |
0.468 |
|
| 2008 |
Mehta J, Frankfurt O, Altman J, Evens AM, Gordon L, Tallman M, Williams S, Winter J, Krishnamurthy J, Grinblatt D, Kaminer L, Singhal S. Factors Affecting the Results of Allogeneic Hematopoietic Stem Cell Transplantation in Hematologic Malignancies Blood. 112: 4386-4386. DOI: 10.1182/Blood.V112.11.4386.4386 |
0.46 |
|
| 2008 |
Singhal S, Mehta R, Krishnamurthy J, Duffey S, Frankfurt O, Evens AM, Altman J, Tallman M, Gordon L, Williams S, Winter J, Mehta J. Cytomegalovirus Seropositivity Does Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation with Intensive Monitoring and Modern Anti-Viral Therapy Blood. 112: 4370-4370. DOI: 10.1182/Blood.V112.11.4370.4370 |
0.41 |
|
| 2008 |
Frankfurt O, Altman J, Krishnamurthy J, Evens AM, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Duffey S, Singh V, Meagher R, Mehta J. The Hematopoietic Cell Transplantation Comorbidity Index: No Effect on Outcome of Reduced-Intensity Allografts. Blood. 112: 1119-1119. DOI: 10.1182/Blood.V112.11.1119.1119 |
0.379 |
|
| 2008 |
Mehta J, Evens AM, Altman J, Frankfurt O, Tallman M, Gordon L, Williams S, Winter J, Krishnamurthy J, Duffey S, Singh V, Meagher R, Singhal S. Optimizing the CD34+ Cell Dose for Allogeneic Transplantation. Blood. 112: 1118-1118. DOI: 10.1182/Blood.V112.11.1118.1118 |
0.479 |
|
| 2008 |
Singh V, Krishnamurthy J, Frankfurt O, Evens AM, Altman J, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J. The Effect of Increasing CD34+ Cell Doses on Time to Engraftment after Autotransplantation for Hematologic Malignancies. Blood. 112: 1115-1115. DOI: 10.1182/Blood.V112.11.1115.1115 |
0.414 |
|
| 2008 |
Trifilio SM, Flickner S, Sheldon S, Pi J, Evens A, Frankfurt O, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J. 364: The Relationship between Tacrolimus Serum Concentrations and Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Recipients Biology of Blood and Marrow Transplantation. 14: 133. DOI: 10.1016/J.Bbmt.2007.12.374 |
0.37 |
|
| 2008 |
Trifilio SM, Pi J, Singhal S, Frankfurt O, Evens A, Gordon L, Tallman M, Winter J, Williams S, Mehta J. 313: Tacrolimus Dosing in Allogeneic Hematopoietic Stem-Cell Transplantation Recipients Receiving Voriconazole Biology of Blood and Marrow Transplantation. 14: 115-116. DOI: 10.1016/J.Bbmt.2007.12.323 |
0.442 |
|
| 2007 |
Molina A, Krishnan A, Fung H, Flinn IW, Inwards D, Winter JN, Nademanee A. Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan. Current Stem Cell Research & Therapy. 2: 239-48. PMID 18220907 DOI: 10.2174/157488807781696230 |
0.393 |
|
| 2007 |
Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, Singhal S, Williams S, Winter J, Tallman M, Gordon L, Frankfurt O, Evens A, Mehta J. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 109: 1532-5. PMID 17351937 DOI: 10.1002/Cncr.22568 |
0.38 |
|
| 2007 |
Singhal S, Frankfurt O, Evens A, Gordon L, Tallman M, Williams S, Winter J, Grinblatt D, Kaminer L, Mehta J. Outcome of Relapse after Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) - The Effect of the Underlying Disease on Survival Following Relapse. Blood. 110: 5020-5020. DOI: 10.1182/Blood.V110.11.5020.5020 |
0.458 |
|
| 2007 |
Trifilio S, Pi J, Singhal S, Frankfurt O, Evens A, Gordon L, Tallman M, Winter J, Williams S, Mehta J. Tacrolimus Dosing in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients Receiving Concomitant Voriconazole. Blood. 110: 4956-4956. DOI: 10.1182/Blood.V110.11.4956.4956 |
0.362 |
|
| 2007 |
Koc O, Redfern C, Wiernik P, Rosenfelt F, Winter J, Guthrie T, Kaplan L, Holman P, Densmore J, Hainsworth J, Lin TS, Castillo R, Janakiraman N, Bender J. Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH) Following Rituximab Induction in Patients (pts) with Follicular B-Cell Lymphoma (FL): Progression Free Survival (PFS) at 4-Year Follow Up. Blood. 110: 2567-2567. DOI: 10.1182/Blood.V110.11.2567.2567 |
0.331 |
|
| 2007 |
Trifilio S, Singhal S, Williams S, Winter J, Tallman M, Gordon L, Evens A, Frankfurt O, Pi J, Mehta J. 429: Voriconazole prophylaxis in patients at high risk for invasive fungal infections following allogeneic hematapoetic stem cell transplantion Biology of Blood and Marrow Transplantation. 13: 153-154. DOI: 10.1016/J.Bbmt.2007.01.060 |
0.403 |
|
| 2006 |
Inwards DJ, Cilley JC, Winter JN. Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma. Best Practice & Research. Clinical Haematology. 19: 669-84. PMID 16997176 DOI: 10.1016/j.beha.2006.05.004 |
0.379 |
|
| 2006 |
Aurora V, Winter JN. Follicular lymphoma: today's treatments and tomorrow's targets. Expert Opinion On Pharmacotherapy. 7: 1273-90. PMID 16805715 DOI: 10.1517/14656566.7.10.1273 |
0.32 |
|
| 2006 |
Boehlke L, Winter JN. Sphingomyelin/cholesterol liposomal vincristine: a new formulation for an old drug. Expert Opinion On Biological Therapy. 6: 409-15. PMID 16548767 DOI: 10.1517/14712598.6.4.409 |
0.321 |
|
| 2006 |
Cilley J, Winter JN. Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas. Haematologica. 91: 114-20. PMID 16434379 |
0.391 |
|
| 2006 |
Aurora V, Winter JN. Current controversies in follicular lymphoma. Blood Reviews. 20: 179-200. PMID 16410034 DOI: 10.1016/j.blre.2005.11.003 |
0.332 |
|
| 2006 |
Mehta J, Gordon L, Tallman M, Winter J, Williams S, Frankfurt O, Evens A, Grinblatt D, Kaminer L, Meagher R, Rashid K, Grabowski D, Singhal S. Reduced-Intesity Allogeneic HSCT in Hematologic Malignancies: Influence of Underlying Diagnosis and Prior Autograft on Outcome. Blood. 108: 3040-3040. DOI: 10.1182/Blood.V108.11.3040.3040 |
0.365 |
|
| 2006 |
Mehta J, Winter J, Tallman M, Gordon L, Williams S, Frankfurt O, Evens A, Grinblatt D, Kaminer L, Meagher R, Singhal S. Submyeloablative Allografts for Hematologic Malignancies: Validation of a Prognostic Model Based on Pre-Transplant Variables. Blood. 108: 3036-3036. DOI: 10.1182/Blood.V108.11.3036.3036 |
0.419 |
|
| 2006 |
Singhal S, Gordon L, Tallman M, Winter J, Williams S, Frankfurt O, Evens A, Meagher R, Kaminer L, Grinblatt D, Mehta J. Submyeloablative Allogeneic HSCT for Hematologic Malignancies: Effect of Body Weight. Blood. 108: 2949-2949. DOI: 10.1182/Blood.V108.11.2949.2949 |
0.353 |
|
| 2006 |
Altman J, Venepalli N, Monreal J, Rashid K, Gordon L, Winter J, Williams S, Tallman M, Frankfurt O, Evens A, Singhal S, Mehta J. Oral Busulfan and Cyclophosphamide or IV Busulfan and Fludarabine for Allogeneic HSCT in Hematologic Malignancies Blood. 108: 2940-2940. DOI: 10.1182/Blood.V108.11.2940.2940 |
0.458 |
|
| 2006 |
Trifilio S, Singhal S, Williams S, Winter J, Tallman M, Gordon L, Frankfurt O, Evens A, Mehta J. Breakthrough Fungal Infections after Allogeneic Hematopoietic Stem Cell Transplantation in Patients on Prophylactic Voriconazole. Blood. 108: 2849-2849. DOI: 10.1182/Blood.V108.11.2849.2849 |
0.381 |
|
| 2005 |
Singhal S, Cetiner M, Gordon L, Evens A, Tallman M, Williams S, Winter J, Meagher R, Mehta J. Factors affecting survival after submyeloablative allogeneic hematopoietic stem cell transplantation (HSCT) for hematologic malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6662. PMID 27944346 DOI: 10.1200/Jco.2005.23.16_Suppl.6662 |
0.434 |
|
| 2005 |
Mehta J, Cetiner M, Gordon L, Evens A, Tallman M, Williams S, Winter J, Meagher R, Singhal S. Effect of impaired renal function on the outcome of submyeloablative allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6666. PMID 27944339 DOI: 10.1200/Jco.2005.23.16_Suppl.6666 |
0.388 |
|
| 2005 |
Winter JN. The role of high-dose therapy followed by autologous purged stem cell transplantation in previously untreated patients with advanced follicular lymphoma. Current Hematology Reports. 4: 249-51. PMID 16009038 |
0.381 |
|
| 2005 |
Neelapu SS, Gause BL, Nikcevich DA, Schuster SJ, Winter J, Gockerman JP, Loughran T, Takeshita K, Inghirami G, McGaughey D, Watson TM, Snow S, Kubovic P, Ferraro M, Jones E, et al. Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report. Clinical Lymphoma. 6: 61-4. PMID 15989711 DOI: 10.3816/Clm.2005.N.031 |
0.365 |
|
| 2005 |
Gidron A, Verma A, Doyle M, Boggio L, Evens A, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies? Bone Marrow Transplantation. 35: 243-246. PMID 15580281 DOI: 10.1038/Sj.Bmt.1704781 |
0.387 |
|
| 2005 |
Koc O, Redfern C, Wiernik P, Rosenfelt F, Winter J, Guthrie T, Kaplan L, Holman P, Densmore J, Hainsworth J, Lin T, Castillo R, Janakiraman N, Gold D, Gutheil J, et al. Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId® (Id/KLH) Vaccine Following Rituximab. Blood. 106: 772-772. DOI: 10.1182/Blood.V106.11.772.772 |
0.36 |
|
| 2005 |
Mehta J, Gordon L, Tallman M, Winter J, Williams S, Evens A, Frankfurt O, Grinblatt D, Kaminer L, Meagher R, Singhal S. Identifying Patients at Risk of Early Relapse after Submyeloablative Allogeneic HSCT. Blood. 106: 5390-5390. DOI: 10.1182/Blood.V106.11.5390.5390 |
0.411 |
|
| 2005 |
Singhal S, Evens A, Frankfurt O, Gordon L, Meagher R, Tallman M, Williams S, Winter J, Kaminer L, Grinblatt D, Mehta J. Graft CD3+ Cell Content Affects Acute GVHD after Submyeloablative Allogeneic HSCT. Blood. 106: 3663-3663. DOI: 10.1182/Blood.V106.11.3663.3663 |
0.45 |
|
| 2005 |
Singhal S, Evens A, Frankfurt O, Gordon L, Meagher R, Tallman M, Williams S, Winter J, Grinblatt D, Kaminer L, Mehta J. Ideal (IBW) Rather Than Actual (ABW) Body Weight Should Be Used To Calculate Cell Dose in Allogeneic HSCT. Blood. 106: 1765-1765. DOI: 10.1182/Blood.V106.11.1765.1765 |
0.437 |
|
| 2005 |
Mehta J, Evens A, Frankfurt O, Gordon L, Grinblatt D, Kaminer L, Meagher R, Tallman M, Williams S, Winter J, Singhal S. Outcome of Submyeloablative Allogeneic HSCT for Hematologic Malignancies: Development of a Prognostic Model Based on Pre-Transplant Characteristics. Blood. 106: 1145-1145. DOI: 10.1182/Blood.V106.11.1145.1145 |
0.417 |
|
| 2005 |
Mehta J, Meagher R, Evens A, Frankfurt O, Singhal S, Tallman M, Williams S, Winter J, Grinblatt D, Kaminer L, Gordon L. The Effect of the Platelet Content of Blood Stem Cell Grafts on GVHD. Blood. 106: 1077-1077. DOI: 10.1182/Blood.V106.11.1077.1077 |
0.446 |
|
| 2004 |
Koc ON, Redfern C, Wiernik P, Rosenfelt F, Winter J, Guthrie T, Kaplan L, Holman P, Densmore J, Hainsworth J. Successful anti-Id T-cell responses to Id-KLH immunotherapy in B-cell depleted patients with follicular lymphoma (FL) may prolong TTP after rituximab: Phase II trial of FavId. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2520. PMID 28015015 DOI: 10.1200/Jco.2004.22.14_Suppl.2520 |
0.325 |
|
| 2004 |
Winter JN. Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. Clinical Lymphoma. 5: S22-6. PMID 15498146 DOI: 10.3816/CLM.2004.S.005 |
0.397 |
|
| 2004 |
Kebriaei P, Winter JN, Laport GG, Le Beau MM, Dewald G, Larson RA. Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantation. Leukemia Research. 28: 537-40. PMID 15068908 DOI: 10.1016/j.leukres.2003.09.010 |
0.366 |
|
| 2004 |
O’Connor O, Wright J, Moskowitz C, MacGregor-Cortelli B, Straus D, Evans A, Winter J, Koc O, Horvath N, Blumel S, Vose J, Schenkein D, Zelenetz A. A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition. Blood. 104: 607-607. DOI: 10.1182/Blood.V104.11.607.607 |
0.361 |
|
| 2004 |
Mehta J, Gordon L, Tallman M, Winter J, Williams S, Evens A, Grinblatt D, Kaminer L, Singhal S. Is a Younger 10-Allele-Matched Unrelated Donor (MUD) Better Than an Older 6-Antigen-Matched Sibling Donor (MSD) for Allogeneic HSCT?. Blood. 104: 2757-2757. DOI: 10.1182/Blood.V104.11.2757.2757 |
0.385 |
|
| 2004 |
Mehta J, Singhal S, Tallman M, Williams S, Winter J, Evens A, Grinblatt D, Kaminer L, Gordon L. Pre-Transplant Variables Affecting the Outcome of Submyeloablative Allogeneic HSCT in Uniformly Treated Patients with Hematologic Malignancies. Blood. 104: 2324-2324. DOI: 10.1182/Blood.V104.11.2324.2324 |
0.405 |
|
| 2004 |
Mehta J, Kwaan H, Gordon L, Evens A, Singhal S, Winter J, Williams S, Rowe J, Goldstone A, Tallman M. Does Concomitant Methotrexate (MTX) and GM-CSF Administration after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Predispose to Thrombotic Microangiopathy (TMA)?. Blood. 104: 1835-1835. DOI: 10.1182/Blood.V104.11.1835.1835 |
0.434 |
|
| 2004 |
Singhal S, Gordon L, Meagher R, Evens A, Tallman M, Williams S, Winter J, Grinblatt D, Kaminer L, Mehta J. The CD34+ Cell Dose, Even in an "Acceptable" Range, Affects Outcome of Allogeneic Blood Stem Cell Transplantation. Blood. 104: 1153-1153. DOI: 10.1182/Blood.V104.11.1153.1153 |
0.46 |
|
| 2004 |
Naik P, Verma A, Pedicano J, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Tempo of neutrophil recovery and the definition of myeloid engraftment after allogeneic hematopoietic stem cell transplantation (HSCT) in patients not receiving growth factors post-transplant Biology of Blood and Marrow Transplantation. 10: 84. DOI: 10.1016/J.Bbmt.2003.12.162 |
0.431 |
|
| 2004 |
Pedicano J, Verma A, Tomblyn M, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Lower post-transplant serum albumin levels predict significantly poorer survival after allogeneic hematopoietic stem cell transplantation Biology of Blood and Marrow Transplantation. 10: 84. DOI: 10.1016/J.Bbmt.2003.12.159 |
0.41 |
|
| 2004 |
Verma A, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Optimizing results of non-myeloablative allogeneic transplantation (NMAT): identification of patients at high risk of treatment failure based upon pre-transplant variables Biology of Blood and Marrow Transplantation. 10: 32. DOI: 10.1016/J.Bbmt.2003.12.141 |
0.371 |
|
| 2004 |
Gidron A, Doyle M, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Tomblyn M, Verma A, Mehta J. Significance of low peripheral blood CD34+ cell numbers prior to leukapheresis: should the 5/μL threshold required for apheresis be changed? Biology of Blood and Marrow Transplantation. 10: 15-16. DOI: 10.1016/J.Bbmt.2003.12.052 |
0.329 |
|
| 2004 |
Gidron A, Verma A, Doyle M, Villa M, Shook T, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies? Biology of Blood and Marrow Transplantation. 10: 62-63. DOI: 10.1016/J.Bbmt.2003.12.027 |
0.387 |
|
| 2003 |
Cilley J, Rihn C, Monreal J, Gordon LI, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplantation. 33: 161-164. PMID 14647242 DOI: 10.1038/Sj.Bmt.1704388 |
0.437 |
|
| 2003 |
Tomblyn M, Winter JN. Autologous hematopoietic stem cell transplant in first remission in non-Hodgkin's lymphoma. Expert Review of Anticancer Therapy. 3: 281-94. PMID 12820773 DOI: 10.1586/14737140.3.3.281 |
0.377 |
|
| 2002 |
Tomblyn M, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea. Bone Marrow Transplantation. 30: 517-519. PMID 12379891 DOI: 10.1038/Sj.Bmt.1703703 |
0.374 |
|
| 2002 |
Mehta J, Singhal S, Gordon L, Tallman M, Williams S, Luyun R, Ali M, Oyama Y, Villa M, Shook T, Winter J. Cobe Spectra is superior to Fenwal CS 3000 Plus for collection of hematopoietic stem cells Bone Marrow Transplantation. 29: 563-567. PMID 11979304 DOI: 10.1038/Sj.Bmt.1703520 |
0.383 |
|
| 2000 |
Patel SD, Guo R, Miller WM, Papoutsakis ET, Minster NI, Baum CM, Winter JN. Clinical-scale production of granulocyte progenitor and post-progenitor cells using daniplestim, leridistim, Progenipoietin, Promegapoietin and autologous plasma. Cytotherapy. 2: 85-94. PMID 12042045 DOI: 10.1080/146532400539080 |
0.49 |
|
| 2000 |
Patel SD, Miller WM, Winter JN, Papoutsakis ET. Cell density-dependent proliferation in frequently-fed peripheral blood mononuclear cell cultures Cytotherapy. 2: 267-280. PMID 12042036 DOI: 10.1080/146532400539206 |
0.479 |
|
| 2000 |
Patel SD, Papoutsakis ET, Winter JN, Miller WM. The lactate issue revisited: novel feeding protocols to examine inhibition of cell proliferation and glucose metabolism in hematopoietic cell cultures. Biotechnology Progress. 16: 885-92. PMID 11027185 DOI: 10.1021/Bp000080A |
0.425 |
|
| 2000 |
Boggio L, Pooley R, Roth S, Winter J. Typhlitis complicating autologous blood stem cell transplantation for breast cancer. Bone Marrow Transplantation. 25: 321-326. PMID 10673706 DOI: 10.1038/Sj.Bmt.1702134 |
0.411 |
|
| 1993 |
Kuzel TM, Rosen ST, Gordon LI, Winter J, Samuelson E, Kaul K, Roenigk HH, Nylen P, Woodworth T. Phase I Trial of the Diphtheria Toxin/Interleukin-2 Fusion Protein DAB486IL-2: Efficacy in Mycosis Fungoides and Other Non-Hodgkin's Lymphomas Leukemia & Lymphoma. 11: 369-377. PMID 8124209 DOI: 10.3109/10428199309067928 |
0.351 |
|
| 1988 |
Marder RJ, Winter J, Epstein A. Heterogeneity of phenotypic expression in normal and neoplastic B-cell proliferations detected by monoclonal antibodies LN-1 and DLC-48 American Journal of Clinical Pathology. 90: 149-155. PMID 3260742 DOI: 10.1093/Ajcp/90.2.149 |
0.358 |
|
| 1984 |
Ueshima Y, Rowley J, Variakojis D, Winter J, Gordon L. Cytogenetic studies on patients with chronic T cell leukemia/lymphoma Blood. 63: 1028-1038. DOI: 10.1182/Blood.V63.5.1028.1028 |
0.317 |
|
| Show low-probability matches. |